TNF (TNFa) Recombinant Human Protein, Invitrogen™ Sino Biological™
This recombinant protein is expressed from a DNA sequence encoding the soluble form of human TNF (NP_000585.2) (Val 77-Leu 233) retaining the initial Met at the N-terminus
Marque: Invitrogen 10602HNAE25
Code nomenclature Nacres: NA.28
Informations supplémentaires : Poids : 0.00001kg
DescriptionTumor necrosis factor alpha (TNF-α) recombinant human protein is supplied as a lyophilized powder. This protein is suitable for use in analysis of protein structure and performing cell based assays. It can also be used as an immunogen, as a protein standard, or in other research applications.&line-break;Background: Tumor necrosis factor alpha (TNF-α), also known as cachectin and TNFSF1A, is the prototypic cytokine of the TNF superfamily, and is a multifunctional molecule involved in the regulation of a wide spectrum of biological processes including cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation. TNF-α is produced mainly by macrophages, and large amounts of this cytokine are released in response to lipopolysaccharide, other bacterial products, and Interleukin-1 (IL-1). TNF-α is primarily produced as a type II transmembrane protein arranged in stable homotrimers, and a soluble trimeric form of TNF-α is released via proteolytic cleavage by the metalloprotease TACE/ ADAM17. Two receptors mediating the TNF-α function have been identified, the ubiquitous TNF RI from which most signaling are derived, and the hematopoietic cell-restricted TNF RII. Upon the TNF-α trimers binding, TNF receptors also form trimers, undergo a conformational change, and enable the adaptor protein TRADD to bind to the death domain, and thus initiates the signal pathways such as the NF-kB, Jak/STAT, and the MAPK pathways, as well as the death signaling. As a major mediator of apoptosis, inflammation and immunity, TNF-α has been implicated in the pathogenesis of a variety of human diseases including autoimmune diseases, insulin resistance, and cancer.
- N-terminal Sequence Analysis: Met
- Activity: measured in a cytotoxicity assay using L929 mouse fibrosarcoma cells in the presence of the metabolic inhibitor actinomycin D, the EC50 for this effect is typically 25-200pg/mL, corresponding to a specific activity of 5 x 106 to 4 x 107 units/mg
- Formulation: lyophilized in 140mM NaCl, 2.7mM KCl, 10mM Na2HPO4, 1.8mM KH2PO4, pH 7.4, 5% mannitol, 5% trehalose, 0.02% Tween™-80
- Reconstitution: Dissolve the protein in sterile double-distilled water to a concentration of 0.2mg/mL or lower; aliquot and use as soon as possible
Manufactured by Sino Biological (China).
|Proteins, Expression, Isolation & Analysis; Enzyme & Protein Activity Assays; Protein Assay Controls, Reference Standards & Accessories|
|5 x 5μg|
|TNF, DADB-70P7.1, DIF, TNF-alpha, TNFA, TNFSF2|
|Cytokines & Receptors|
|≥95% by SDS-PAGE|
|Store at -20°C. Store aliquots under sterile conditions at -20°C. Avoid repeated freeze-thaw cycles. Expires one year from date of receipt when stored as instructed.|
|TNF (Tumor Necrosis Factor)|
|Tumor necrosis factor|
For Research Use Only. Not for use in diagnostic procedures.